1. Metastatic Male Breast Cancer With Increased Uptake on 18F-Fluciclovine PET/CT Scan
- Author
-
Bital Savir-Baruch, David T. Greenwald, Funmilayo Tade, Harkanwar S. Gill, and Paul M. Yonover
- Subjects
Male ,medicine.medical_specialty ,Carboxylic Acids ,Elevated blood ,Breast Neoplasms, Male ,030218 nuclear medicine & medical imaging ,Food and drug administration ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Recurrence ,Prostate ,Positron Emission Tomography Computed Tomography ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Aged ,Prior treatment ,Incidental Findings ,PET-CT ,business.industry ,Prostatic Neoplasms ,Biological Transport ,General Medicine ,medicine.disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Male breast cancer ,Recurrent prostate cancer ,Radiology ,business ,Cyclobutanes - Abstract
Prostate imaging with F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC, F-fluciclovine) PET/CT scan (Axumin) was recently approved by the US Food and Drug Administration for men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen levels following prior treatment. We present a rare case of a 77-year-old man with suspected recurrent prostate cancer with an incidental finding of advanced-stage breast cancer showing different degrees of F-fluciclovine uptake.
- Published
- 2018
- Full Text
- View/download PDF